title: The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis.
abstract: The chemokine, epithelial neutrophil-activating peptide-78 (ENA-78), is a potent neutrophil chemotaxin whose expression is increased in inflamed synovial tissue and fluid in human rheumatoid arthritis compared with osteoarthritis. Since ENA-78 has been implicated in the pathogenesis of RA, we examined the expression of an ENA-78-like protein during the development of rat adjuvant-induced arthritis (AIA). Using an ELISA assay, we found increased levels of antigenic ENA-78-like protein in the sera of AIA animals compared with control normal animals by day 7 postadjuvant injection. ENA-78-like protein levels continued to increase as AIA developed. ENA-78-like protein levels in joint homogenates were increased in AIA animals later in the development of the disease, by day 18 during maximal arthritis, compared with control animals. Expression of ENA-78-like protein in both the AIA serum and joint correlated with the progression of inflammation of the joints. Anti-human ENA-78 administered before disease onset modified the severity of AIA, while administration of anti-ENA-78 after clinical onset of AIA did not modify the disease. These data support a role for an ENA-78-like protein as an important chemokine in the progression and maintenance of AIA.
authors.affiliation: Department of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Halloran
authors.forename: J M
authors.initials: JM
authors.lastname: Woods
authors.forename: R M
authors.initials: RM
authors.lastname: Strieter
authors.forename: Z
authors.initials: Z
authors.lastname: Szekanecz
authors.forename: M V
authors.initials: MV
authors.lastname: Volin
authors.forename: S
authors.initials: S
authors.lastname: Hosaka
authors.forename: G K
authors.initials: GK
authors.lastname: Haines
authors.forename: S L
authors.initials: SL
authors.lastname: Kunkel
authors.forename: M D
authors.initials: MD
authors.lastname: Burdick
authors.forename: A
authors.initials: A
authors.lastname: Walz
authors.forename: A E
authors.initials: AE
authors.lastname: Koch
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D002465:Cell Movement / Q000276:immunology; D054365:Chemokine CXCL5; D019743:Chemokines, CXC; D004847:Epithelial Cells / Q000276:immunology; D005260:Female; D007106:Immune Sera / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D016209:Interleukin-8 / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000097:blood / Q000276:immunology / Q000502:physiology; D018375:Neutrophil Activation / Q000276:immunology*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D010537:Peritoneum / Q000276:immunology / Q000473:pathology; D051381:Rats; D011917:Rats, Inbred Lew; D013582:Synovial Fluid / Q000276:immunology / Q000378:metabolism; D013643:Tarsus, Animal; D013997:Time Factors
chemical_list: C486263:CXCL5 protein, human; D054365:Chemokine CXCL5; D019743:Chemokines, CXC; D007106:Immune Sera; D016209:Interleukin-8